Rubinstein et al v. Gonzalez et al

  1. October 25, 2019

    $16.7M AbbVie Inversion Settlement Gets Final Approval

    An Illinois federal judge has approved a $16.75 million settlement for investors who claimed pharmaceutical company AbbVie hid the tax risks of its failed $54 billion merger with Shire PLC.

  2. September 18, 2019

    Attys Seek $5M Award In AbbVie $16.7M Inversion Settlement

    An Illinois federal judge has been asked to approve a $5 million payday for attorneys who negotiated a $16.75 million settlement of investors' claims that pharmaceutical company AbbVie hid the risks of its failed $54 billion merger with Shire PLC.

  3. July 03, 2019

    AbbVie's $16.7M Inversion Settlement Gets Initial Approval

    An Illinois federal judge has given preliminary approval to a $16.75 million agreement to settle a claim that pharmaceutical maker AbbVie misled investors about risks of its failed $54 billion merger with Irish rival Shire PLC.

  4. June 19, 2019

    AbbVie, Investors Reach $17M Deal Over Failed Inversion

    Drugmaker AbbVie Inc. has reached a $16.75 million agreement to settle a claim that it misled investors about the risks of its failed $54 billion merger with Irish pharmaceutical company Shire PLC, according to documents filed Wednesday in Illinois federal court.

  5. April 11, 2019

    AbbVie To Settle With Shire Investors Over Failed $55B Tie-Up

    Investors suing AbbVie Inc. over the failed $55 billion merger with Shire PLC have reached a deal to end their claims that the biopharma giant misled them about why it was seeking a tie-up with the Irish pharmaceutical company, according to a notice in Illinois federal court.

  6. September 26, 2018

    Expert's Analyses Questioned In AbbVie Merger Cert. Row

    Amid a contentious class certification battle for Shire PLC investors suing AbbVie Inc. over the companies' failed merger, the Illinois federal judge overseeing the case said Tuesday he needs more briefing on the investors' expert before he can rule on the certification.

  7. March 10, 2017

    AbbVie Must Face Investors' Suit Over Failed $55B Merger

    An Illinois federal judge refused to toss a shareholder suit against pharmaceutical giant AbbVie Inc. over its failed $55 billion merger with Irish pharmaceutical company Shire PLC, finding Friday that a letter to shareholders by the company's CEO could be construed as reckless under federal securities laws.

  8. January 19, 2017

    AbbVie Fires Back At Investors' Suit Over Failed Merger

    Pharmaceutical giant AbbVie Inc. told an Illinois federal judge Wednesday that a new proposed class action in county court accusing the company of common law fraud does not allege anything the U.S. District Court has not already rejected.

  9. March 29, 2016

    AbbVie Escapes Shire Investors' Suit Over Failed Merger

    An Illinois judge Tuesday tossed a proposed class action by Shire PLC shareholders alleging AbbVie Inc. harmed them by downplaying the importance of tax incentives in a failed $55 billion merger of the drug companies, saying the plaintiffs didn’t show that AbbVie had misled Shire investors.

  10. May 19, 2015

    Shire Investors Say AbbVie Can't Ax Suit Over Failed Inversion

    A putative class of Shire PLC shareholders said Monday that AbbVie Inc. must face claims that it harmed investors by downplaying the tax incentives for the drugmakers' $55 billion merger, which fell apart last year amid the Obama administration's crackdown on tax-driven corporate inversions.